The Therapeutic Role of Soluble Adenylyl Cyclase Inhibition in Ameliorating Inf
Closed Special Notice Posted
- Solicitation number
- 75N98026Q01067
- Agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The National Heart, Lung and Blood Institute issued a Notice of Intent on August 28, 2026 for a non-competitive service contract award to The Johns Hopkins University for collection of de-identified biospecimens and clinical data related to pulmonary arterial hypertension research, with responses due by September 4, 2026 at 10:00 a.m. EDT. This is a sole-source acquisition exempt from FAR Part 6 competition requirements; Johns Hopkins was designated the clinical collaborator under a 2024 Bench-to-Bedside and Back Award that funds the work.
The 12-month contract, valued at $41.5 million and classified under NAICS 621511 (Medical Laboratories), requires collection of peripheral blood mononuclear cells and associated clinical data from approximately 30 patients: 10 with systemic sclerosis-associated PAH, 10 with systemic sclerosis without PAH, and 10 with idiopathic PAH. The Johns Hopkins Pulmonary Hypertension Program, an accredited Comprehensive Care Center, will enroll patients at an anticipated rate of 2 per month. The contractor must follow IRB-approved protocols for venipuncture, process PBMCs within two hours, cryopreserve samples in liquid nitrogen, and transfer de-identified samples to NHLBI upon completion. Associated clinical data includes demographics, functional classification, exercise tolerance, imaging results, hemodynamic measurements, cardiac biomarkers, and medications. Interested parties may submit capability statements, proposals, or quotations to James Hawkins (james.hawkins3@nih.gov) and Natalie Bruning (Natalie.bruning@nih.gov).
Notice text
The Therapeutic Role of Soluble Adenylyl Cyclase Inhibition in Ameliorating Inflammatory Vascular Remodeling in Pulmonary Arterial Hypertension
Files
| File | Type | Posted |
|---|---|---|
| Notice_of_Intent_co_review_1.pdf |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Clinical Research Support and Collaboration for NHGRI Protocols | Office of Logisitics and Acquisition Operations | Total Small Business | |
| CSS - Upgrading PExA 2.1 to Vial-Based (PExA Cap) | Office of Logisitics and Acquisition Operations | No set-aside | |
| Brain Repair of Any Injured Neural Structure (BRAINS) - Proposers' Day | National Institutes of Health | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity